| Literature DB >> 25964637 |
David S Ettinger1, Douglas E Wood1, Wallace Akerley1, Lyudmila A Bazhenova1, Hossein Borghaei1, David Ross Camidge1, Richard T Cheney1, Lucian R Chirieac1, Thomas A D'Amico1, Todd L Demmy1, Thomas J Dilling1, M Chris Dobelbower1, Ramaswamy Govindan1, Frederic W Grannis1, Leora Horn1, Thierry M Jahan1, Ritsuko Komaki1, Lee M Krug1, Rudy P Lackner1, Michael Lanuti1, Rogerio Lilenbaum1, Jules Lin1, Billy W Loo1, Renato Martins1, Gregory A Otterson1, Jyoti D Patel1, Katherine M Pisters1, Karen Reckamp1, Gregory J Riely1, Eric Rohren1, Steven E Schild1, Theresa A Shapiro1, Scott J Swanson1, Kurt Tauer1, Stephen C Yang1, Kristina Gregory1, Miranda Hughes1.
Abstract
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.Entities:
Mesh：
Year: 2015 PMID： 25964637 DOI： 10.6004/jnccn.2015.0071
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908